logo
The Government to Stop Tracking the Costs of Extreme Weather

The Government to Stop Tracking the Costs of Extreme Weather

New York Times08-05-2025

The National Oceanic and Atmospheric Administration said on Thursday it would stop tracking the cost of the country's most expensive disasters, those which cause at least $1 billion in damage.
The move would leave insurance companies, researchers and government policymakers without information to help understand the patterns of major disasters like hurricanes, drought or wildfires, and their economic consequences, starting this year.Those events are becoming more frequent or severe as the planet grows hotter, although not all disasters are linked to climate change.
It's the latest effort from the Trump administration to restrict or eliminate climate research. In recent weeks the administration has dismissed the authors working on the nation's biggest climate assessment, planned to eliminate National Parks grants focused on climate change, and released a budget plan that would cut significantly climate science from the U.S. Geological Survey and the Energy and Defense departments.
Researchers and lawmakers criticized Thursday's decision.
Jesse M. Keenan, associate professor and director of the Center on Climate Change and Urbanism at Tulane University in New Orleans, said ending the data collection would cripple efforts by federal and state governments to set budgets or make decisions on investment in infrastructure.
'It defies logic,' he said. Without the database, 'the U.S. government's flying blind as to the cost of extreme weather and climate change.'
Few institutions can duplicate the kind of information provided by the database, said Virginia Iglesias, a climate researcher at the University of Colorado. 'It's one of the most consistent and trusted records of climate-related economic loss in the country,' she said. 'The power of the database lies in its credibility.'
So-called billion-dollar disasters — those with costs that balloon to seven figures are more — have been increasing over time. In the 1980s, when NOAA began compiling these lists, there were just over three per year, on average, when adjusted for inflation. For the period from 2020 to 2024, the average was 23 per year.
In total, at least 403 such events have occurred in the United States since 1980. Last year there were 27, a tally second only to 2023 (which had 28).
Last year's disasters included hurricanes Helene and Milton, which together caused about $113 billion in damages and more than 250 deaths, a severe hailstorm in Colorado that caused about $3 billion in damages and a yearlong drought across much of the country that caused $5 billion in damages and claimed the lives of more than 100 people from heat exposure.
NOAA's National Centers for Environmental Information plans to stop tracking these billion-dollar disasters in response to 'evolving priorities, statutory mandates, and staffing changes,' the agency said in an email.
When asked, the agency did not say whether another branch of NOAA or federal agency would continue tracking and publicly reporting the price tag of such disasters. The announcement said the agency would make archived data from 1980 to 2024 available. But the dollar amount of disasters from 2025 on, such as the Los Angeles wildfires and their estimated billions of dollars of damage, would not be tracked and reported to the public.
'You can't fix what you don't measure,' said Erin Sikorsky, the director of The Center for Climate and Security. 'If we lose this information about the costs of these disasters, the American people and Congress won't know what risks climate is posting to our country.'
Other institutions or agencies would likely be unable to duplicate the data collection because it includes proprietary insurance information that companies are cautious to share, Ms. Sikorsky said. 'It's a pretty unique contribution.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Salvadoran at the heart of row over Trump's deportation policies arrested on return to the US
Salvadoran at the heart of row over Trump's deportation policies arrested on return to the US

News24

time17 minutes ago

  • News24

Salvadoran at the heart of row over Trump's deportation policies arrested on return to the US

The Salvadoran migrant at the heart of a row over President Donald Trump's hardline deportation policies was returned to the United States on Friday and arrested on human smuggling charges. Kilmar Armando Abrego Garcia was brought back to the United States from El Salvador and charged with trafficking undocumented migrants, Attorney General Pam Bondi said. "Abrego Garcia has landed in the United States to face justice," Bondi said at a press conference. The US Supreme Court had ordered the Trump administration to "facilitate" the return of Abrego Garcia after he was mistakenly deported in March to a notorious maximum security prison in El Salvador. But Bondi insisted to reporters that his return to the United States resulted from an arrest warrant presented to Salvadoran authorities. "We're grateful to (Salvadoran) President (Nayib) Bukele for agreeing to return him to our country to face these very serious charges," she said. In a post on X, Bukele said "we work with the Trump administration, and if they request the return of a gang member to face charges, of course we wouldn't refuse." Trump, in remarks to reporters Friday, described Abrego Garcia as a "pretty bad guy" and said he "should've never had to be returned." White House deputy press secretary Abigail Jackson said Abrego Garcia's return "has nothing to do with his original deportation." "There was no mistake," Jackson said on X. "He's returning because a new investigation has revealed crimes SO HEINOUS, committed in the US, that only the American Justice System could hold him fully accountable." Abrego Garcia, 29, was living in the eastern state of Maryland until he became one of more than 200 people sent to a prison in El Salvador as part of Trump's crackdown on undocumented migrants. Most of the migrants who were summarily deported were alleged members of the Venezuelan gang Tren de Aragua, which the Trump administration has declared a foreign terrorist organisation. 'Administrative error' Justice Department lawyers later admitted that Abrego Garcia - who is married to a US citizen - was wrongly deported due to an "administrative error." Abrego Garcia had been living in the United States under protected legal status since 2019, when a judge ruled he should not be deported because he could be harmed in his home country. Simon Sandoval-Moshenberg, one of Abrego Garcia's attorneys, said the government had returned him to the United States "not to correct their error but to prosecute him." "Due process means the chance to defend yourself before you're punished, not after," Sandoval-Moshenberg said. "This is an abuse of power, not justice." Bondi alleged that Abrego Garcia had "played a significant role in an alien smuggling ring" and was a smuggler of "children and women" as well as members of the Salvadoran gang MS-13. She said Abrego Garcia, who was indicted by a grand jury in Tennessee, would be returned to El Salvador upon completion of any prison sentence. Democratic Senator Chris Van Hollen visited Abrego Garcia in April in El Salvador and welcomed his return to the United States. "For months the Trump Administration flouted the Supreme Court and our Constitution," the senator from Maryland said in a statement. "Today, they appear to have finally relented to our demands for compliance with court orders and with the due process rights afforded to everyone in the United States," he said. "The Administration will now have to make its case in the court of law, as it should have all along." According to the indictment, Abrego Garcia was involved in smuggling undocumented migrants from Guatemala, El Salvador, Honduras and other countries into the United States between 2016 and earlier this year.

Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Ask the Expert: Should I have Biomarker Testing – and Would it Help?

Health Line

time23 minutes ago

  • Health Line

Ask the Expert: Should I have Biomarker Testing – and Would it Help?

Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.

2025 Box Office Bomb Dominates HBO Max
2025 Box Office Bomb Dominates HBO Max

Screen Geek

time24 minutes ago

  • Screen Geek

2025 Box Office Bomb Dominates HBO Max

Subscribers on HBO Max are flocking to one of 2025's box office bombs as the film unexpectedly tops the streaming service's charts. Of course, it's not surprising that this 2025 effort is doing so well on HBO Max following its theatrical release, especially when one considers that it comes from an acclaimed director. As noted via FlixPatrol, at the time of this writing, this film is the #2 title on the streaming platform. It's quite a feat for a movie that struggled at the box office, having earned just barely more than its budget at the box office, grossing $132 million against a $118 million production cost. Impressively, the title stars Robert Pattinson as the lead, with Naomi Ackie, Steven Yeun, Toni Collette, and Mark Ruffalo. Bong Joon Ho both wrote and directed the film which was based on a novel by Edward Ashton. It seems as though the talent from everyone involved has given this title legs beyond its theatrical release. This 2025 film now streaming on HBO Max is none other than Mickey 17 , a sci-fi film set in the year 2054. It revolves around Pattinson's character who joins a space colony. His official title is that of an 'Expendable,' which is an individual that happens to be cloned upon death. While a majority of their memories are retained, they quickly become diluted with each additional copy. It's an interesting endeavor from Bong Joon Ho, and one that probably should have fared better at the box office. Fortunately, it looks like it has been earning viewers with its newfound availability on HBO Max and home video. Stay tuned to ScreenGeek for any additional updates regarding the latest trending titles on HBO Max as we have them. For now, subscribers are able to see Mickey 17 for themselves, and see whether or not the title was deserving of a better box office performance. Especially now that it appears to be doing quite well on streaming.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store